Hyaluronic acid may predict severity & prognosis of community-acquired pneumonia: Study

In CAP patients, increased Hyaluronic acidlevels were more pronounced in those with SCAP (SCAP vs non-SCAP:135.6 ± 51 ng/mL vs 100.7 ± 47.8 ng/mL, P < 0.001). Compared to survivors (109.9 ± 48.7 ng/mL), Hyaluronic acid levels in non-survivors were significantly higher (180.9 ± 67.8 ng/mL) (P < 0.001). Hyaluronic acid was an independent predictor of SCAP [odds ratio (OR): 1.013, 95% confidence interval (CI): 1.003– 1.022, P = 0.011] with high diagnostic accuracy [areas under the curve (AUC): 0.709, 95% CI: 0.622– 0.797, P = 0.001].

Additionally, Hyaluronic acid was independently associated with death risk in patients with CAP (OR: 1.022, 95% CI: 1.005– 1.039, P = 0.010). Kaplan-Meier survival curves indicated that CAP patients in the high HA group exhibit a higher 30-day mortality rate compared to those in the low Hyaluronic acid group (8.6% vs 1.5%, P = 0.008).

Post hoc analysis indicated that our study possessed 98.857% statistical power. In conclusion, High Hyaluronic acid levels are associated with severity and mortality in patients with CAP, and Hyaluronic acid could serve as a novel serum biomarker to predict the risk of CAP progression.

Reference:

Lin Y, Li Y, Cui X, Zhu N, Li X. Hyaluronic Acid is Associated with Severity and Prognosis in Patients with Community-Acquired Pneumonia. J Inflamm Res. 2024;17:11881-11895https://doi.org/10.2147/JIR.S499326